PEOPLE - Changes at Boston Scientific:
This article was originally published in Clinica
Executive Summary
Dr Philip Le Goff has been appointed group president of Boston Scientific's vascular businesses (Meadox, Medi-Tech and Target Therapeutics). He joins from Novartis Pharma. Additionally, the US company has appointed Michel Darnaud president of Boston Scientific Europe. He was previously president-Europe of Baxter International's Cardiovascular Group.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.